Our technological innovation platform called “CleanWeb-MAP” (CleanWeb Managed Access Programme) facilitates access to new drugs by eligible patients.
There are multiple terms that fall under the umbrella of MAP, including Compassionate Use, Early Access, Named Patient Use and Individual Patient Request Programmes to name but a few. The terms used may vary from country to country depending on local laws and regulations. Our module is closely linked to our CleanWeb software platform for medical data collection, it enables self-registration of prescribing physicians and pharmacists, for each new product related to MAP.
• MAPs provide alternative treatments to patients with life-threatening diseases with no therapeutic options
• CleanWeb-MAP meets local laws and regulations Seamless Managed Access Programmes
Entrust your project
to our expert
data management team
Allows you to gain valuable early experience with a product
CleanWeb-MAP facilitates the management of MAPs in real-life conditions
Each role and access are clearly defined Physicians, Nurses, Medical Advisor, Programme Manager, Pharmacovigilance officer, Logistics perfectly interact in the MAP cycle process.
The ordering process and the availability of drugs are assured in interaction with any external system and data source.
CleanWeb-MAP allows for the involvement of other stakeholders and for the integration of many additional behaviours (e.g., Pharmacist).
Do you want to learn more about our e-health solution? Just fill in the form and we will get back to you shortly
A LEADING POSITION AND
AN INTERNATIONAL DEPLOYMENT
64 +
countries
involved
20 000 +
investigational
Centres
3 million +
patients
in database
50 000 +
users
worlwide
January 30, 2025
MedtechDive Artificial intelligence was a topic of focus for the medical device industry in 2024. Companies including GE Healthcare, Medtronic and Dexcom touted new AI features, and others like Stryker and Quest Diagnostics added AI assets through M&A. Meanwhile, conversations about regulations and generative AI, models that are trained to create new data including images and text, dominated medtech conferences. The Food and Drug Administration recently […]
January 30, 2025
BioPharm International FDA published a final guidance on Jan. 2, 2025 for those interested in participating in the agency’s Advanced Manufacturing Technologies Designation Program, which was developed to facilitate drugs manufactured using advanced manufacturing technologies (AMTs). The guidance, Advanced Manufacturing Technologies Designation Program, is the final version of the draft document issued on Dec. 13, 2023. […]
January 30, 2025
Applied Clinical Trials Online Medable has shared new data from the Tufts Center for the Study of Drug Development (CSDD)’s PACT Consortium linking decentralized clinical trial (DCT) approaches to a higher rate in participation across multiple demographic groups. The new research shows that a more strategic implementation of DCT elements, combined with increased regulatory oversight, […]